香港股市 已收市

MRK Jun 2023 70.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
37.84+1.20 (+3.28%)
收市價: 10:48AM EST
全螢幕
前收市價36.64
開市37.84
買盤37.40
賣出價38.15
拍板70.00
到期日2023-06-16
今日波幅37.84 - 37.84
合同範圍
成交量2
未平倉合約15
  • Benzinga

    Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients

    Merck & Co Inc (NYSE: MRK) has announced topline results from the pivotal Phase 3 KEYNOTE-859 trial of its flagship anti-PD-1 therapy, Keytruda, in gastric or Gastroesophageal Junction GEJ adenocarcinoma. The trial evaluated Keytruda in combination with chemotherapy for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. Related: Five-Year Data For Merck's Keytruda Plus Chemo Shows Sustain

  • Insider Monkey

    These 10 Stocks are Skyrocketing Today

    In this article, we will take a look at the 10 stocks skyrocketing today. If you want to check out some other stocks gaining value on Monday, go directly to These 5 Stocks are Skyrocketing Today. U.S. stocks inched lower this morning as investors feared that China might reimpose mobility restrictions following the resurgence of […]

  • Benzinga

    Cancer-Focused Imago BioSciences Shares Soar After Merck Deal

    Merck & Co Inc (NYSE: MRK) has agreed to acquire Imago BioSciences Inc (NASDAQ: IMGO) for $36.00 per share in cash for an approximate total equity value of $1.35 billion. "This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology," commented Merck's President & CEO, Robert Davis. Imago is a clinical-stage biopharmaceutical company developing new medicines for myeloproliferative neoplasms (MPNs) and other bone marrow diseases. Related: Centre